Myocardial Infarction - Pipeline Review, H2 2017

Publisher Name :
Date: 12-Sep-2017
No. of pages: 289
Inquire Before Buying

Myocardial Infarction - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Infarction - Pipeline Review, H2 2017, provides an overview of the Myocardial Infarction (Cardiovascular) pipeline landscape.

Myocardial infarction is the irreversible necrosis of heart muscle secondary to prolonged ischemia. Symptoms include pain, fullness, and/or squeezing sensation of the chest, jaw pain, toothache, headache, shortness of breath, nausea, vomiting, and/or general epigastric discomfort, sweating, heartburn and/or indigestion, arm pain, upper back pain and general malaise (vague feeling of illness).

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myocardial Infarction - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Myocardial Infarction (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myocardial Infarction (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Infarction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 11, 11, 45, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 20 and 7 molecules, respectively.

Myocardial Infarction (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Infarction (Cardiovascular).

- The pipeline guide reviews pipeline therapeutics for Myocardial Infarction (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Myocardial Infarction (Cardiovascular) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Myocardial Infarction (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Infarction (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Myocardial Infarction (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Myocardial Infarction (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Myocardial Infarction - Pipeline Review, H2 2017

Table of Contents
Table of Contents 2
Introduction 5
Myocardial Infarction - Overview 6
Myocardial Infarction - Therapeutics Development 7
Myocardial Infarction - Therapeutics Assessment 22
Myocardial Infarction - Companies Involved in Therapeutics Development 34
Myocardial Infarction - Drug Profiles 56
Myocardial Infarction - Dormant Projects 260
Myocardial Infarction - Discontinued Products 266
Myocardial Infarction - Product Development Milestones 267
Appendix 277

List of Tables
Number of Products under Development for Myocardial Infarction, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Universities/Institutes, H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Myocardial Infarction - Pipeline by Amarantus Bioscience Holdings Inc, H2 2017
Myocardial Infarction - Pipeline by AstraZeneca Plc, H2 2017
Myocardial Infarction - Pipeline by Athersys Inc, H2 2017
Myocardial Infarction - Pipeline by Bayer AG, H2 2017
Myocardial Infarction - Pipeline by Bharat Biotech International Ltd, H2 2017
Myocardial Infarction - Pipeline by BioCardia Inc, H2 2017
Myocardial Infarction - Pipeline by Biscayne Pharmaceuticals Inc, H2 2017
Myocardial Infarction - Pipeline by C&C BioPharma LLC, H2 2017
Myocardial Infarction - Pipeline by Cadila Healthcare Ltd, H2 2017
Myocardial Infarction - Pipeline by CellProthera, H2 2017
Myocardial Infarction - Pipeline by Chrysalis BioTherapeutics Inc, H2 2017
Myocardial Infarction - Pipeline by Cynata Therapeutics Ltd, H2 2017
Myocardial Infarction - Pipeline by Diffusion Pharmaceuticals Inc, H2 2017
Myocardial Infarction - Pipeline by FibroGen Inc, H2 2017
Myocardial Infarction - Pipeline by Hemostemix Ltd, H2 2017
Myocardial Infarction - Pipeline by Human Stem Cells Institute, H2 2017
Myocardial Infarction - Pipeline by HUYA Bioscience International LLC, H2 2017
Myocardial Infarction - Pipeline by InCarda Therapeutics Inc, H2 2017
Myocardial Infarction - Pipeline by Juventas Therapeutics Inc, H2 2017
Myocardial Infarction - Pipeline by K-Stemcell Co Ltd, H2 2017
Myocardial Infarction - Pipeline by Laboratoires Pierre Fabre SA, H2 2017
Myocardial Infarction - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2017
Myocardial Infarction - Pipeline by LG Chem, Ltd., H2 2017
Myocardial Infarction - Pipeline by Lonestar Heart Inc, H2 2017
Myocardial Infarction - Pipeline by Mesoblast Ltd, H2 2017
Myocardial Infarction - Pipeline by miRagen Therapeutics Inc, H2 2017
Myocardial Infarction - Pipeline by Moderna Therapeutics Inc, H2 2017
Myocardial Infarction - Pipeline by Navya Biologicals Pvt Ltd, H2 2017
Myocardial Infarction - Pipeline by New World Laboratories Inc, H2 2017
Myocardial Infarction - Pipeline by Novartis AG, H2 2017
Myocardial Infarction - Pipeline by NuvOx Pharma LLC, H2 2017
Myocardial Infarction - Pipeline by Omeros Corp, H2 2017
Myocardial Infarction - Pipeline by Opsona Therapeutics Ltd, H2 2017
Myocardial Infarction - Pipeline by Otsuka Holdings Co Ltd, H2 2017
Myocardial Infarction - Pipeline by Prolong Pharmaceuticals LLC, H2 2017
Myocardial Infarction - Pipeline by Quark Pharmaceuticals Inc, H2 2017
Myocardial Infarction - Pipeline by Reata Pharmaceuticals Inc, H2 2017
Myocardial Infarction - Pipeline by Recardio GmbH, H2 2017
Myocardial Infarction - Pipeline by RegeneRx Biopharmaceuticals Inc, H2 2017
Myocardial Infarction - Pipeline by Reliance Life Sciences Pvt Ltd, H2 2017
Myocardial Infarction - Pipeline by Rubicon Biotechnology Inc, H2 2017
Myocardial Infarction - Pipeline by Serodus ASA, H2 2017
Myocardial Infarction - Pipeline by Silver Creek Pharmaceuticals Inc, H2 2017
Myocardial Infarction - Pipeline by TaiGen Biotechnology Co Ltd, H2 2017
Myocardial Infarction - Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2017
Myocardial Infarction - Pipeline by TiGenix NV, H2 2017
Myocardial Infarction - Pipeline by Vicore Pharma AB, H2 2017
Myocardial Infarction - Pipeline by XBiotech Inc, H2 2017
Myocardial Infarction - Pipeline by Yuyu Pharma Inc, H2 2017
Myocardial Infarction - Dormant Projects, H2 2017
Myocardial Infarction - Dormant Projects, H2 2017 (Contd..1), H2 2017
Myocardial Infarction - Dormant Projects, H2 2017 (Contd..2), H2 2017
Myocardial Infarction - Dormant Projects, H2 2017 (Contd..3), H2 2017
Myocardial Infarction - Dormant Projects, H2 2017 (Contd..4), H2 2017
Myocardial Infarction - Dormant Projects, H2 2017 (Contd..5), H2 2017
Myocardial Infarction - Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Myocardial Infarction, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Top 10 Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017
  • Global and United States Coronary Artery Disease Therapeutics Market Research by Company, Type & Application 2013-2025
    Published: 11-Jun-2018        Price: US 2000 Onwards        Pages: 114
    Summary Market Segment as follows: By Type - Beta-blockers - Calcium channel blockers - Nitrates - ACE inhibitors By Application - Drugstore - Hospital - Others By Company - AstraZeneca - Gilead - Novartis - Pfizer - Bayer - Bristol-Myers Squibb - GlaxoSmithKline - Merck - Mylan - Teva Pharmaceutical Industries ......
  • China Angina Pectoris Treatment Market Research Report 2018
    Published: 17-May-2018        Price: US 3400 Onwards        Pages: 109
    The global Angina Pectoris Treatment market is valued at XX million USD in 2017 and is expected to reach XX million USD by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. China plays an important role in global market, with market size of xx million USD in 2017 and will be xx million USD in 2025, with a CAGR of xx%. This report studies the Angina Pectoris Treatment development status and future trend in China, focuses on top players in China, also s......
  • Indonesia Angina Pectoris Treatment Market Research Report 2018
    Published: 17-May-2018        Price: US 3400 Onwards        Pages: 108
    The global Angina Pectoris Treatment market is valued at XX million USD in 2017 and is expected to reach XX million USD by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Indonesia plays an important role in global market, with market size of xx million USD in 2017 and will be xx million USD in 2025, with a CAGR of xx%. This report studies the Angina Pectoris Treatment development status and future trend in Indonesia, focuses on top players in Indon......
  • Global Coronary Artery Disease Therapeutics Market Data Survey Report 2025
    Published: 04-May-2018        Price: US 1500 Onwards        Pages: 69
    Summary The global Coronary Artery Disease Therapeutics market will reach Volume Million USD in 2018 with CAGR xx% 2018-2025. The main contents of the report including: Global market size and forecast Regional market size, production data and export & import Key manufacturers (manufacturing sites, capacity and production, product specifications etc.) Major Application Major Type Key manufacturers are included based on manufacturing......
  • Global Angina Pectoris Treatment Market Professional Survey Report 2018
    Published: 27-Apr-2018        Price: US 3500 Onwards        Pages: 117
    This report studies Angina Pectoris Treatment in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2013 to 2018, and forecast to 2025. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Abbott Laboratories Inc. - Astra Zeneca plc - Bayer AG - B......
  • United States Angina Pectoris Treatment Market Report 2018
    Published: 05-Apr-2018        Price: US 3800 Onwards        Pages: 109
    In this report, the United States Angina Pectoris Treatment market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share a......
  • Global Coronary Artery Disease Therapeutics Market Research Report 2011-2023
    Published: 02-Apr-2018        Price: US 2280 Onwards        Pages: 85
    Summary The global Coronary Artery Disease Therapeutics market will reach xxx Million USD in 2018 with CAGR xx% 2018-2023. The objective of report is to define, segment, and project the market on the basis of product type, application, and region, and to describe the content about the factors influencing market dynamics, policy, economic, technology and market entry etc. Based on products type, the report describes major products type share of regional market. Produ......
  • Global Myocardial Infarction Partnering 2012 to 2018
    Published: 01-Apr-2018        Price: US 1995 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." Summary The Global Myocardial Infarction Partnering since 2012 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in partnering deals - Top deals by value - Deals listed by company A-Z, industry sector, stage of development, technology type The report provides......
  • Global Congestive Heart Failure Partnering 2012 to 2018
    Published: 01-Apr-2018        Price: US 1995 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." Summary The Global Congestive Heart Failure Partnering since 2012 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in partnering deals - Top deals by value - Deals listed by company A-Z, industry sector, stage of development, technology type The report provi......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs